4516
Nippon Shinyaku Co.,Ltd.
日本新薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Notes
- Accounting standardsIFRS / Since Mar 2022
Key metrics
Revenue(million JPY)
Mar 2021
121,885
Mar 2022
137,484
Mar 2023
144,175
Mar 2024
148,255
Mar 2025
160,232
Operating profit(million JPY)
Mar 2021
26,134
Mar 2022
32,948
Mar 2023
30,049
Mar 2024
33,295
Mar 2025
35,450
Operating profit margin(%)
Mar 2021
21.44
Mar 2022
23.96
Mar 2023
20.84
Mar 2024
22.46
Mar 2025
22.12
Profit before tax(million JPY)
Mar 2021
28,759
Mar 2022
33,301
Mar 2023
30,489
Mar 2024
33,616
Mar 2025
36,135
Profit(million JPY)
Mar 2021
20,702
Mar 2022
24,986
Mar 2023
22,812
Mar 2024
25,851
Mar 2025
32,558
Total assets(million JPY)
Mar 2021
197,028
Mar 2022
219,943
Mar 2023
237,451
Mar 2024
263,404
Mar 2025
283,637
Cash and cash equivalents(million JPY)
Mar 2021
57,883
Mar 2022
60,566
Mar 2023
60,047
Mar 2024
58,094
Mar 2025
55,241
Cash flows from operating activities(million JPY)
Mar 2021
21,388
Mar 2022
21,316
Mar 2023
26,170
Mar 2024
16,289
Mar 2025
36,126
Cash flows from investing activities(million JPY)
Mar 2021
-1,564
Mar 2022
-10,037
Mar 2023
-17,631
Mar 2024
-9,921
Mar 2025
-28,877
Cash flows from financing activities(million JPY)
Mar 2021
-6,199
Mar 2022
-8,407
Mar 2023
-9,605
Mar 2024
-9,719
Mar 2025
-9,902
Return on equity(%)
Mar 2021
13.5
Mar 2022
14.5
Mar 2023
12.1
Mar 2024
12.4
Mar 2025
13.9
Equity ratio(%)
Mar 2021
82.4
Mar 2022
82.1
Mar 2023
82.4
Mar 2024
83.6
Mar 2025
87.1
Earnings per share(JPY per share)
Mar 2021
307.37
Mar 2022
370.97
Mar 2023
338.7
Mar 2024
383.82
Mar 2025
483.4
Net assets per share(JPY per share)
Mar 2021
2,409.01
Mar 2022
2,681.18
Mar 2023
2,904.49
Mar 2024
3,269.72
Mar 2025
3,666.27
Dividend per share(JPY per share)
Mar 2021
99
Mar 2022
110
Mar 2023
114
Mar 2024
124
Mar 2025
124
Payout ratio(%)
Mar 2021
32.21
Mar 2022
29.65
Mar 2023
33.66
Mar 2024
32.31
Mar 2025
25.65
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.